Evaluation Period vs Control Period: Viral Suppression
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.902 | 0.891 | 0.912 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.942 | 0.935 | 0.949 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.0404 | -0.0532 | -0.0279 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.957 | 0.944 | 0.97 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.563 | 0.472 | 0.672 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer participant with the outcome on Evaluation Period than on Control Period | 24.8 | 18.8 | 35.9 | from the risk difference interval | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: control.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Evaluation Period | Patients monitored during the evaluation period. | 2,830 | 3,138 | OG001 | ClinicalTrials.gov |
| Group 2 | Control Period | Patients monitored during the control period. | 3,849 | 4,085 | OG000 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | SECONDARY | ClinicalTrials.gov |
| Title | Viral Suppression | ClinicalTrials.gov |
| Description | Viral suppression, will be defined as HIV RNA \<200 copies/mL at last test closest to the time of data extraction, consistent with Department of Health and Human Services (DHHS) guidelines. Although current limits of detection are lower, this cutoff allows for low-level blips that have no clinical significance. | ClinicalTrials.gov |
| Time frame | 12 months | ClinicalTrials.gov |
| Population | All patients monitored across all control (multiple) and evaluation periods. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Working With HIV Clinics to Adopt Addiction Treatments Using Implementation Facilitation | ClinicalTrials.gov |
| NCT number | NCT02907944 | ClinicalTrials.gov |
| Phases | NA | ClinicalTrials.gov |
| Conditions | Substance-related Disorders | ClinicalTrials.gov |
| Interventions | Implementation Facilitation | ClinicalTrials.gov |
| Lead sponsor | Yale University | ClinicalTrials.gov |
| Results first posted | 2023-05-08 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT02907944?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.